Ordinary Reweighting | RBC Biotech Opportunities Index Series 2 | Effective Date 3rd October 2022

In the ordinary reweighting the following composition will be implemented effective open 03.10.2022:

ABBVIE INC
AGIOS PHARMACEUTICALS INC
ALNYLAM PHARMACEUTICALS INC
AMGEN INC
BIOGEN INC
ELI LILLY & CO
GILEAD SCIENCES INC
INCYTE CORP
INTRA-CELLULAR THERAPIES INC
KARUNA THERAPEUTICS INC
PACIRA BIOSCIENCES INC
SAREPTA THERAPEUTICS INC
SEAGEN INC
XENON PHARMACEUTICALS INC